Joseph Cappello sold $14k of GNLX
VP, Pharmaceutical Development at GENELUX Corp. 4,737 shares at an average of $2.92, traded May 12, 2025, filed May 13, 2025.
Score components
- +15RoleOfficer
- 0Trade size$14k at market
- 0Share of holdings soldSold 8.3% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-012806, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 12, 2025 | SOpen-market sale Common Stock | -4,737 | $2.92 | $14k | 52,266 | May 13, 2025 |
Related signals
Other insiders at GENELUX Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | GENELUX Corp | Joseph Cappello Chief Technical Officer | $28k 10,257 shares | -3% | |
| 35Weak | GENELUX Corp | Yong Yu Chief Scientific Officer | $27k 9,683 shares | -4% | |
| 49Moderate | GENELUX Corp | Thomas Zindrick President and CEO | $92k 34,463 shares | -3% | |
| 30Weak | GENELUX Corp | Joseph Cappello Chief Technical Officer | $2,193 906 shares | -1% | |
| 40Moderate | GENELUX Corp | Thomas Zindrick President and CEO | $8,668 3,582 shares | -1% | |
| 30Weak | GENELUX Corp | Yong Yu SVP, Clinical Development | $2,193 906 shares | -1% | |
| 30Weak | GENELUX Corp | Ralph Smalling Head of Regulatory | $1,437 585 shares | -1% | |
| 0Weak | GENELUX Corp | John Thomas director | $29k 10,000 shares | -2% | |
| 30Weak | GENELUX Corp | Joseph Cappello Chief Technical Officer | $14k 3,706 shares | -2% | |
| 30Weak | GENELUX Corp | Yong Yu SVP, Clinical Development | $16k 4,192 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.